Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

Item
http://www.wikidata.org/entity/Q33389907
Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women(R)- and (S)-methadone and buprenorphine concentration ratios in maternal and umbilical cord plasma following chronic maintenance dosing in pregnancyAgonist-antagonist combinations in opioid dependence: a translational approachNovel approaches for the treatment of psychostimulant and opioid abuse - focus on opioid receptor-based therapies.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.Intravenous buprenorphine and norbuprenorphine pharmacokinetics in humans.Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects.High-sensitivity analysis of buprenorphine, norbuprenorphine, buprenorphine glucuronide, and norbuprenorphine glucuronide in plasma and urine by liquid chromatography-mass spectrometryA physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy.Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers.Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine.Buprenorphine in the treatment of opiate dependence.Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.The Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine.A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm.Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction.
P2860

Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

Item
http://www.wikidata.org/entity/Q33389907
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@ast
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@en
type
label
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@ast
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@en
prefLabel
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@ast
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Pharmacokinetics of high-dose ...... eers under a naltrexone block.
@en
P2093
P304
P31
P356
10.1016/S0376-8716(03)00188-1
P433
P478
P577
P698
P921